PUBLICATIONS

 ARTICLES PUBLISHED IN JOURNALS/BOOKS

 

2014

75. Katgı A, Sevindik OG, Gokbulut AA, Ozsan HG, Yuksel F, Solmaz SM, Alacacıoglu I, Ozcan MA, Demirkan F, Baran Y, Piskin O.  Nilotinib Does Not Alter the Secretory Funcions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion. In Press, 2014, Clinical and Applied Thrombosis/Hemostasis.

74. Cincin ZB, Unlu M, Kıran B, Bireller ES, Baran Y*, Cakmakoglu B*. Apoptotic Effects of Quercitrin in DLD-1 Colon Cancer Cell Lines. In Press, 2014, Pathology and Oncology Research.

73. Cincin ZB, Unlu M, Kıran B, Bireller ES, Baran Y*, Cakmakoglu B*. Molecular Mechanisms of Quercitrin-Induced Apoptosis in Non Small Cell Lung Cancer Cells. In Press, 2014, Archives of Medical Research.

72- Unlu M, Kiraz Y, Kacı FN, Baran Y*. Multidrug Resistance In Chronic Myeloid Leukemia. In Press, 2014, Turkish Journal of Biology.

71- Kiraz Y, Unlu M, Kartal Yandim M, Baran Y*. Molecular Biology of Stem Cells. In Press, 2014, Hematolog (Invited Book Chapter). 

70- Gokbulut AA, Baran Y*. A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells. In Press, 2014, Turkish Journal of Hematology.

69- Celikkanat D, Baran Y*. Comparative development of knowledge-based bioeconomy in the European Union and Turkey.  Critical Reviews in Biotechnology, 2014; 34(3): 269-280.

68- Solmaz S, Gokbulut AA, Cincin B, Ozdogu H, BogaC, Cakmakoglu B, Kozanoglu I, Baran Y*. Therapeutic Potential of Apigenin, a Plant Flavonoid, for Imatinib-Sensitive and Resistant Chronic Myeloid Leukemia Cells. Nutrition and Cancer; An International Journal, 2014; 66(4): 599-612. 

67- Omur O, Baran Y*.  An Update on Molecular Biology of Thyroid Cancers. Critical Reviews in Oncology/Hematology, 2014; 90(3): 233-252.

66- Y, Adan Gokbulut A, Baran Y, Yemenicioglu A*. Bioactive, functional and edible film making properties of different protein isolates from Turkish hazelnut (Corylus avellana L.) meal obtained from oil extraction. Food Hydrocolloids, 2014; 36:130-142.

65- Avci CB, Baran Y*. Micro RNAs in Personilized medicine. Methods in Molecular Biology; miRNomics: MicroRNA Biology and Computational Analysis, Humana Press, 2014, 1107:311-25

64- Ömür Ö*, Baran Y, Oral A, Ceylan Y. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography For Extranodal Staging Of Non-Hodgkin Lymphoma And Hodgkin Disease. Diagnostic and Interventional Radiology 2014;0(2):185-192.

 

2013

63- Yilmaz AF, Saydam G, Sahin F, Baran Y*. Granulocytic Sarcoma: A Systematic Review. American Journal of Blood Research, 2014; 3(4):265-270.

62- Comert M, Baran Y*, Saydam G. Changes in moleculer biology of Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor era. 2013; (3):191-200.American Journal of Blood Research.

61-  Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M*. 5-Fluouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene, 2013; 32(38):4529-4538.

60-  Baran Y*, Ceylan C, Camgoz A. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy. Biomedicine and Pharmacotherapy, 2013; 67: 221-22

59- Gokbulut AA, Yandım MK, Iskender G, Baran Y*. Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer. Current Medicinal Chemistry, 2013, 20: 108-122.

58- Kartal YandımM, Apohan E, Baran Y*. Therapeutic Potential of Targeting Ceramide/Glucosylceramide Pathway in Cancer. Cancer Chemotherapy and Pharmacology, 2013; 71(1): 13-20.

57-  Kaymaz BT, Selvi N, Adan Gokbulut A, Aktan Ç, Gündüz C, Saydam G, Şahin F, Çetintaş VB, Baran Y, Kosova B*. Suppression of STAT5A and STAT5B Chronic Myeloid Leukemia Cells via siRNA and Antisense-Oligonucleotide Applications with the Induction of Apoptosis. American Journal of Blood Research, 2013; 3(1): 58-70.

56-  Kozanoglu I, Yandim MK, Cincin ZB, Ozdogu H, Cakmakoglu B, Baran Y*. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. Journal of Cancer Research and Clinical Oncology. 2013; 139(2): 327-335.

55-  Senarisoy M, Canturk P, Zencir S, Baran Y, Topcu Z*. Gossypol interferes with both type I and type II topoisomerases activities without generating strand breaks. Cell Biochemistry and Biophysics,2013; 66(1): 199-204.

54- Turan T, Sanlı-Mohamed G, Baran Y*. Changes in Protein Profiles of Multiple Myeloma Cells in Response to Bortezomib. Leukemia and Lymphoma, 2013;54(5):1061-1068.

53- Camgoz A, Gencer EB, Ural AU, Baran Y*. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. Leukemia and Lymphoma, 2013; 54(6): 1279-1287.

52- Ozgur O, Can G, Cakir Z, Denek Z, Kozanoğlu I, Erdil G, Mustafa M, Baran Y*. Autologous Rabbit Adipose Tissue Derived Mesenchymal Stem Cells For The Treatment Of Bone Injuries With Distraction Osteogenesis. Cytotherapy, 2013; 15(6): 690-702.

51- Firatligil B, Avci CB, Baran Y*. mir-17 in Imatinib Resistance and Response to Tryosine Kinase Inhibitors in Chronic Myeloid Leukemia Cells.J. BUON. 2013; 18(2): 437-441.

50- Adan-Gokbulut A, Apohan E, Baran Y*. Resveratrol and quercetin induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology, 2013; 18(3):144-50.

49- Bozkurt S*, Özkan T, Özmen F, Baran Y, Sunguroğlu A, Kansu E. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells. Hematology, 2013; 18(4): 217-223.

48- Kiper HD, Tezcanli B, Gokbulut AA, Selvi N, Avci CB, Kosova BK, Iskender G, Yandım MK, Gunduz C, Sahin F, Baran Y*, Saydam G. STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomedicine and Pharmacotherapy, 2013; 67(6):527-532.

 

2012

47- Ekiz HA, Can G, Baran Y*. Role of autophagy in the progression and suppression of leukemias. Critical Reviews in Hematology/Oncology, 2012; 81(3): 275-285.

46- Bassoy EY and Baran Y*. Bioactive Sphingolipids In Docetaxel-Induced Apoptosis In Human Prostate Cancer Cells. Biomedicine And Pharmacotherapy, 2012 66(2): 103-110.

45- Ceylan C, Camgoz A, Baran Y*. Macromolecular changes in nilotinib resistant K562 cells; an in vitro study by Fourier transform infrared spectroscopy. Technology in Cancer Research & Treatment, 2012; 11(4): 333-344.

44- Can G, Cakir Z, Kartal M, Gunduz U, Baran Y*. Apoptotic Effects of Resveratrol, a Grape Polyphenol, On Imatinib Sensitive And Resistant K562 Cronic Myeloid Leukemia Cells. Anticancer Research, 2012; 32(7): 2673-2678.

43-     Kozanoğlu İ*, Baran Y. Molecular Diagnostic Techniques in Hematology Laboratory. Turkish Journal of Medical Sciences, Under Revision, 2012; 5(4):87-94.

42- Baran Y*, Saydam G. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of Chronic Myeloid Leukemia. Journal of Blood Medicine, 2012; 3: 139–150.

41- Purclutepe O, Iskender G, Kiper HD, Tezcanli B, Selvi N, Avci CB, Kosova B, Sahin F, Baran Y*, Saydam G. Enalapril-Induced Apoptosis of Acute Promyeloctic Leukemia Cells  Involves STAT5A. Anticancer Research, 2012; 32: 2885-2894.

40- Bozcuk H, Abali H, Coskun S, Aydıner A, Çinkaya A, Demirkazık A, Özet A, Yolcu A, Balkan A, Çavdar A, Kefeli AÜ, Uluç BO, Atasoy B, Demirkan B, Yalçın B, Eroğlu C, Yalman D, Kılıç D, Tunalı D, Fırat D, Seber E, Üçgül Çavuşoğlu E, Ulukaya E, Kaytan Sağlam E, Tezcanlı E, Eryılmaz E, Dinçbaş FÖ, Telli F, Yumuk F, Başaran G, Çağlar HB, Sönmez H, Yılmaz H, Engin H, Helvacı K, Sönmez K, Koral L, Artaç M, Fuat Eren M, Koçar M, Beyzadeoğlu M, Akın M, Benekli M, Cengiz M, Erman M, Yıldız M, Doğan M, Balkan M, Eraktuğ N, Ünal OÜ, Şencan O, Erpolat Ö, Saip P, Kılıçkap S, Selçuk Seber SO, Paydaş S, Sarıhan S, Kömürcü Ş, Demirkasımoğlu T, Korkmaz T, Yetişyiğit T, Yavuzşen T, Evrensel T, Akman T, Abacıoğlu U, Kefeli U, Egeli Ü, Elgin Y, Baran Y, Bulut Z (Alphabetical order). The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World Journal of Surgical Oncology, 2012; 10(1):161-167.

 

2011

39- Kartal M, Saydam G, Sahin, Baran Y*. Resveratrol Triggers Apoptosis by Increasing Intracellular Concentrations of Ceramides in Chronic Myeloid Leukemia Cells. Nutrition and Cancer; An International Journal, 2011; 63(4): 637-644.

39- Can G, Ekiz A, Baran Y*. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells. Hematology, 2011; 16(2): 95-99.

37- Avcı CB, Gunduz C, Baran Y, Sahin F, Yilmaz S, Dogan ZO, Saydam G*. Caffeic Acid Phenethyl Esther Triggers Apoptosis Through Induction of Loss of Mitochondrial Membrane Potential in CCRF-CEM. Journal of Cancer Research and Clinical Oncology, 2011; 137: 41-47. 

36- Gencer EB, Ural AU, Avcu F, Baran Y*.Dasatinib Induces Apoptosis Through Increasing de novo Generation or Accumulation of Ceramides in Human K562 and Meg-01 Chronic Myeloid Leukemia Cells. Annals of Hematology, 2011; 90(11): 1265-1275.

35- Camgoz A, Ural AU, Avcu F, Baran Y*. Targeting Ceramide Metabolism to Increase Intracellular Concentrations of Apoptotic Ceramide Increased Cytotoxic Effects of Nilotinib in Human Chronic Myeloid Leukemia Cells. Leukemia and Lymphoma, 2011; 52(8): 1574-1584.

34- Ekiz HA, Baran Y*. Bioactive Sphingolipids in Response to Chemotherapy: A Scope on Leukemias. Anti-Cancer Agents in Medicinal Chemistry, 2011; 11: 385-397.

33- Salas A, Ponnusamy S, Senkal CE, Meyers MA, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Ramasamy S, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart RK, Perrotti D, Ogretmen B*. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood, 2011; 117(22): 5941-5952.

32- Baran Y, Zencir S, Çakır Z, Öztürk E, Topçu Z*.  Imatinib-induced apoptosis; A possible link to topoisomerase enzyme inhibition. Journal of Clinical Pharmacy and Therapeutics, 2011; 36(6): 673-679.

31- Avcu F, Avcu N*, Er N, Kansu Ö, Baran Y, Pekel A, Ural AU. The Cytotoxic and  Apoptotic-Necrotic Effects of Whitening Materials on Human Gingival Fibroblasts.  Clinical Dentistry and Research, 2011; 35(1): 3-11.

30- Baran Y*, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. Journal of Cancer Research and Clinical Oncology, 2011; 137(10): 1535-1544.

29-Sanli MG, Turan T, Ekiz HA, Baran Y*. Importance of Protein Profiling in Diagnosis and Treatment of Hematological Malignancies. Turkish Journal of Hematology, 2011; 28: 1-14.

28- Cakir Z, Saydam G, Sahin F, Baran Y*. The Roles Of Bioactive Sphingolipids In Resveratrol-Induced Apoptosis In HL60 Acute Myeloid Leukemia Cells. Journal Of Cancer Research And Clinical Oncology, 2011; 137: 279–286.

27- Avcı ÇB, Yılmaz S, Dogan ZO, Saydam G, Dodurga Y, Ekiz HA, Kartal M, Sahin F, Baran Y*, Gunduz C. Quercetin-induced Apoptosis involves increased HTERT enzyme activity of Leukemic Cells. Hematology, 2011; 16(5): 303-307.

26- Firinci F*, Karaman M, Baran Y, Bagriyanik A, Ayyildiz ZA, Kiray M, Kozanoglu I, Yilmaz O, Uzuner N, Karaman O. Mesenchymal Stem Cells Ameliorate The Histopathological Changes in a Murine Model of Chronic Asthma. International Immunopharmacology, 2011; 11(8): 1120-1126.

25- Mutlu P, Baran Y, Ural AU, Avcu F, Dirican B, Beyzadeoglu M, Gündüz U*. Effect Of Cobalt-60 (Γ Radiation) On Multidrug Resistant Multiple Myeloma Cell Lines. Cell Biology International, 2011; 35(7): 721-725.

24- Gucluler G, Piskin O, Baran Y*. The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells. J BUON, 2011; 16(4): 646-651.

23- Baran Y*. Gene Transfer Techniques in Cell Death Research. 2011, Book Chapter, 1st Theoritical Cell Death Research Techniques Course, ISBN: 978-975-441-349-6.

22- Baran Y*. Critical Decision of Cells; Die or Survive. 2011, Book Chapter, 1st Theoritical Cell Death Research Techniques Course, ISBN: 978-975-441-349-6.

21- Adan A, Kartal M, Baran Y*. Molecular Biology of Breast Cancer. 2011, Book Chapter, Molecular Approaches to Breast Cancer, ISBN: 978-975-483-928-9.

 

2010

20. Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, Baran Y*. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leukemia and Lymphoma, 2010; 51(10): 1895-1901. 

19. Ekiz HA, Baran Y*. Therapeutic Applications of Bioactive Sphingolipids in Hematological Malignancies. International Journal of Cancer, 2010; 127(7): 1497-1506.

18. Baran Y*,Oztekin C, Bassoy EY. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myeloid leukemia cells. Cancer Investigation, 2010; 28(6): 623-628.

17. Goktas S, Baran Y, Ural AU, Yazici S*, Aydur E, Basal S,  Avcu F, Pekel A, Dirican B, Beyzadeoglu M.Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells. Urology, 2010; 75(4): 793-798.

16. Ekiz HA, Can G, Gunduz U, Baran Y*. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts. Hematology, 2010; 15(1): 33-38.

 

2009

15. Baran Y*, Oztekin C, Bassoy EY. Inhibition of Proteasome by Bortezomib Increased Chemosensitivity of BCR/ABL Positive Human K562 Chronic Myleoid Leukemia Cells to Imatinib. Health, 2009; 1(4): 320-324.

14. Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli Ua, Baran Y, Uslu R*. Docetaxel/Zoledronic Acid Combination Triggers Apoptosis Synergistically Through Downregulating Antiapoptotic Bcl-2 Protein Level In Hormone-Refractory Prostate Cancer Cells. Cell Biology International, 2009; 33(2): 239-46.

13. Abaan DO, Mutlu PK, Baran Y, Atalay MC, Gunduz U*. Multidrug Resistance Mediated by MRP1 Gene Overexpression in Breast Cancer Patients.Cancer Investigation, 2009; 7(2): 201-205.

12. Gucluler G, Baran Y*. Docetaxel Enhances the Cytotoxic Effects of Imatinib on Philadelphia Positive Human Chronic Myeloid Leukemia Cells. Hematology, 2009; 14(3): 139-144.

 

2008

11. Ural AU*, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Medical Oncology, 2008; 25(3): 350-355.

10. Baran Y*,Ural AU, Avcu F, Sarper M, Elçi P, Pekel A. Optimisation of Transfection of Green Flourescent Protein in Pursuing Mesenchymal Stem Cells, In Vivo. Turkish Journal of Hematology.2008; 25(4): 172-175.

 

2007

9. Gorduysus M*, Avcu N, Gorduysus O, Pekel A, Baran Y,Avcu F, Ural AU. Cytotoxic Effects of Four Different Endodontic Materials on Human Periodontal Ligament Fibroblasts. Journal of Endodontics, 2007; 33(12): 1450-1454.

8. Ural AU*, Avcu F, Baran Y. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 2007; 110(2): 469-470.

7. Baran Y*,Gunduz U.Genetics of chronic myeloid leukemia.Journal of Turkish Internal Medicine, 2007; 3(2): 50-55.

6. Baran Y*,Gur B, Ural AU, Avcu F, Gunduz U. Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology, 2007; 12(6): 511-517.

5. Baran Y*,Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology, 2007; 12(6): 497-503.

4. Baran Y,Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B*. Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells. Journal of Biological Chemistry, 2007; 282(15): 10922-10934.

 

2006

3. Baran Y*,Gunduz U, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Experimental Oncology, 2006; 28(2): 163-165.

 

2005

2. Önalan G*, Selam B, Baran Y,Cincik M, Onalan R, Gündüz U, Ural AU, Pabuççu R. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. Human Reproduction. 2005; 20(9): 2391-2395.

1. Baran Y*,Gündüz U, Ural AU. Expression of multi drug resistance (MDR1) gene in human promyelocytic leukemia cell line selected with vincristine. Turkish Journal of Cancer. 2005; 35(2): 88-92.

 

*Corresponding Author

ABSTRACTS PUBLISHED IN NATIONAL AND INTERNATIONAL CONFERENCES

We have more than 150 abstracts published in national/international congress.